Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Depreciation & Amortization (IS): 2010-2025

Historic Depreciation & Amortization (IS) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Sep 2025 value amounting to $22.6 million.

  • Ani Pharmaceuticals' Depreciation & Amortization (IS) rose 43.71% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.4 million, marking a year-over-year increase of 51.52%. This contributed to the annual value of $67.7 million for FY2024, which is 13.28% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Depreciation & Amortization (IS) is $22.6 million, which was down 2.79% from $23.3 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Depreciation & Amortization (IS) registered a high of $23.3 million during Q2 2025, and its lowest value of $10.9 million during Q1 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (IS) was $15.2 million (2023), whereas its average is $17.8 million.
  • In the last 5 years, Ani Pharmaceuticals' Depreciation & Amortization (IS) dropped by 2.55% in 2021 and then skyrocketed by 58.41% in 2025.
  • Ani Pharmaceuticals' Depreciation & Amortization (IS) (Quarterly) stood at $13.7 million in 2021, then climbed by 5.85% to $14.5 million in 2022, then grew by 4.90% to $15.2 million in 2023, then surged by 48.74% to $22.6 million in 2024, then spiked by 43.71% to $22.6 million in 2025.
  • Its Depreciation & Amortization (IS) was $22.6 million in Q3 2025, compared to $23.3 million in Q2 2025 and $22.9 million in Q1 2025.